Stable angina: drugs, angioplasty or surgery?

Area of Science:

• Cardiology
• Internal Medicine

Background:

• Stable angina is a prevalent condition with a generally favorable prognosis, exhibiting an annual mortality rate of 2-4% across various treatments.
• Current medical therapy, including nitrates, beta-blockers, calcium antagonists, and lipid-lowering agents, serves as appropriate first-line treatment for many patients.

Purpose of the Study:

• To evaluate the comparative effectiveness and prognostic implications of medical therapy, coronary artery bypass grafting (CABG), and percutaneous transluminal coronary angioplasty (PTCA) in managing stable angina.
• To determine the optimal utilization of these treatment modalities for symptomatic relief.

Main Methods:

• Review of existing literature comparing medical therapy, CABG, and PTCA for stable angina.
• Analysis of prognostic data and symptomatic relief associated with each treatment modality.

Main Results:

• Coronary artery bypass grafting (CABG) may improve prognosis in high-risk patients compared to older medical therapy trials, but recent medical advances and arterial grafts are not fully accounted for.
• Percutaneous transluminal coronary angioplasty (PTCA) effectively relieves symptoms when medical therapy fails but its role as initial therapy and comparison to CABG regarding revascularization and re-intervention remain unclear.
• PTCA offers a less invasive, less expensive alternative to CABG with quicker recovery, providing symptomatic benefit for selected patients.

Conclusions:

• Medical therapy, PTCA, and CABG should be viewed as complementary, not competitive, treatment strategies for stable angina.
• Optimal management involves judicious use of all three modalities, alone or in combination, to achieve substantial symptomatic relief for patients.